Pathstone Holdings LLC Has $1.48 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Pathstone Holdings LLC grew its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 4.1% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 4,118 shares of the biotechnology company’s stock after acquiring an additional 163 shares during the period. Pathstone Holdings LLC’s holdings in United Therapeutics were worth $1,476,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. ClariVest Asset Management LLC raised its stake in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the period. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics in the second quarter valued at about $30,000. Innealta Capital LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth about $33,000. USA Financial Formulas bought a new stake in shares of United Therapeutics during the 3rd quarter worth about $33,000. Finally, Capital Performance Advisors LLP acquired a new position in United Therapeutics in the 3rd quarter valued at about $82,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

NASDAQ UTHR opened at $378.13 on Friday. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82. The business has a fifty day moving average price of $366.89 and a two-hundred day moving average price of $334.15. The stock has a market capitalization of $16.88 billion, a PE ratio of 16.61, a PEG ratio of 1.07 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s revenue was up 22.9% compared to the same quarter last year. During the same period last year, the firm posted $5.38 earnings per share. As a group, sell-side analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $960,576.75. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,485,785.60. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 127,227 shares of company stock worth $47,398,820 in the last three months. 11.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on UTHR. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. The Goldman Sachs Group boosted their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Oppenheimer increased their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH upped their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.